The UC Berkeley spin-out aims to develop one-time treatments for chronic and rare diseases using an RNA- and LNP-based platform.

Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes ...

All-RNA, non-viral, LNP-based PRINT™ platform is designed to develop safer, durable, one-time therapies for a broad range of unmet needsAddition ...

University of California spinout Addition Therapeutics has uncloaked, revealing “breakthrough” PRINT technology it hopes will ...

All-RNA, non-viral, LNP-based PRINT™ platform is designed to develop safer, durable, one-time therapies for a broad range of unmet needsAddition is advancing a robust pipeline of PRINTed therapeutics ...

Addition Therapeutics came out of stealth mode to highlight its Precise RNA-Mediated Insertion of Transgenes (PRINT) gene ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Alfred Olivares, global managing partner, healthcare & ...

And Simon Kohl, founder and CEO of Latent Labs, knows this intimately. In a new episode of the pharmaphorum podcast, Kohl ...

Eli Lilly (LLY) has reached a research and licensing agreement worth up to $1.2B with SanegeneBio to develop and commercialize RNAi therapeutics for metabolic diseases, the Boston, Massachusetts-based ...

BOSTON, Nov. 8, 2025 /PRNewswire/ -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli ...

Flashy wealth is out. Quiet wealth is in. In 2025, it's not the person posting luxury vacations on Instagram who's winning; it's the one with a paid-off mortgage and maxed-out retirement accounts. The ...

It was not until 2018 that the US FDA approved the first therapy developed using the technique. Since then, there’s been a steady, but slow, number of RNAi treatments coming into the market. The ROBO ...